CN108114061A - Use of Chinese herbal medicine extract and pharmaceutical composition containing the same and steroid - Google Patents
Use of Chinese herbal medicine extract and pharmaceutical composition containing the same and steroid Download PDFInfo
- Publication number
- CN108114061A CN108114061A CN201611205417.7A CN201611205417A CN108114061A CN 108114061 A CN108114061 A CN 108114061A CN 201611205417 A CN201611205417 A CN 201611205417A CN 108114061 A CN108114061 A CN 108114061A
- Authority
- CN
- China
- Prior art keywords
- herbal medicine
- skin disease
- medicine extract
- chinese herbal
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 134
- 241000411851 herbal medicine Species 0.000 title claims abstract description 99
- 150000003431 steroids Chemical class 0.000 title claims description 92
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 208000017520 skin disease Diseases 0.000 claims abstract description 131
- 239000003814 drug Substances 0.000 claims abstract description 74
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 36
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 28
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 239000002674 ointment Substances 0.000 claims description 139
- 238000012545 processing Methods 0.000 claims description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 229940079593 drug Drugs 0.000 claims description 63
- 230000000694 effects Effects 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 52
- 201000010099 disease Diseases 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 41
- 229910052709 silver Inorganic materials 0.000 claims description 41
- 239000004332 silver Substances 0.000 claims description 41
- 235000019441 ethanol Nutrition 0.000 claims description 40
- 241000736199 Paeonia Species 0.000 claims description 35
- 238000000605 extraction Methods 0.000 claims description 25
- 241000202726 Bupleurum Species 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 24
- 230000006872 improvement Effects 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000006208 topical dosage form Substances 0.000 claims description 18
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 15
- 235000014676 Phragmites communis Nutrition 0.000 claims description 15
- 229940010454 licorice Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 201000008937 atopic dermatitis Diseases 0.000 claims description 14
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 13
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 230000005784 autoimmunity Effects 0.000 claims description 9
- 229960002537 betamethasone Drugs 0.000 claims description 9
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 229960001048 fluorometholone Drugs 0.000 claims description 7
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 7
- 229960001011 medrysone Drugs 0.000 claims description 7
- 229960005205 prednisolone Drugs 0.000 claims description 7
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 7
- 229960005294 triamcinolone Drugs 0.000 claims description 7
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 7
- 208000022535 Infectious Skin disease Diseases 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 3
- 241001506371 Kadsura Species 0.000 claims description 3
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 3
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 8
- 235000019640 taste Nutrition 0.000 claims 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 2
- 235000011613 Pinus brutia Nutrition 0.000 claims 2
- 241000018646 Pinus brutia Species 0.000 claims 2
- 125000005909 ethyl alcohol group Chemical group 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 89
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 72
- 229960002751 imiquimod Drugs 0.000 description 66
- 239000006071 cream Substances 0.000 description 37
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 27
- 229960001347 fluocinolone acetonide Drugs 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 238000010171 animal model Methods 0.000 description 22
- 230000006698 induction Effects 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 229960002842 clobetasol Drugs 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 238000005520 cutting process Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000013691 Interleukin-17 Human genes 0.000 description 10
- 108050003558 Interleukin-17 Proteins 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 9
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical class [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- CNXNMLQATFFYLX-ICTDYHGOSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol;[2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-10,13,16-trime Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CNXNMLQATFFYLX-ICTDYHGOSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 229940060265 aldara Drugs 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- -1 liquor Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 240000001307 Myosotis scorpioides Species 0.000 description 5
- 208000005775 Parakeratosis Diseases 0.000 description 5
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 206010040799 Skin atrophy Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960002882 calcipotriol Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008311 hydrophilic ointment Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003303 reheating Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004703 clobetasol propionate Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- CUHVTYCUTYWQOR-UHFFFAOYSA-N formaldehyde Chemical compound O=C.O=C CUHVTYCUTYWQOR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of a Chinese herbal medicine extract in preparing a medicament for treating skin diseases, wherein the Chinese herbal medicine extract is prepared from raw materials of liquorice, radix bupleuri, scutellaria baicalensis, schisandra chinensis and Chinese herbaceous peony.
Description
Technical field
The present invention relates to a kind of purposes of Chinese herbal medicine extract and the medical composition containing this herb extract and steroids.
Background technology
Skin disease is the most common disease in the whole world, and about 1/3 population is present with a kind of pathologic in life in it
Skin problem, and in being paid in health-care, skin related medical expenditure is also up to 25%.
Skin disease is divided into four major classes, and respectively dermatitis (for example, anaphylaxis and contact), cancer are (for example, melanin
Knurl), immunological diseases (for example, silver bits disease) and infectious skin disease (for example, bacterium, fungi and virus infection).
Topical steroid is widely used in all kinds of skin diseases, especially Atopic dermatitis and silver bits disease, and in
Serious dermatitis sufferer, steroids dosage higher.Many is classified as the compound of steroids (steroid), example
As betamethasone (betamethasone) or hydrogenation Bo Nisong (prednisolone) are non-for the effect for treating inflammatory diseases
Chang Hao, however, these compound long-time services may also but cause the atrophoderma of sufferer.If sufferer is during steroid therapy
There is the phenomenon that atrophoderma, be then generally considered to be steroids reactor (steroid responders).Atrophoderma pair
In the influence of the sufferer (e.g., silver bits disease sufferer) with skin disease symptom be to be worth concern.It is even however, normal
Skin in the case of long-time service steroids, is also present with the side effect of skin injury.
Therefore, the research and development of the secure replacement drug of steroids and/or the effect of how topical steroid to be maintained to treat and subtract
Few side effect is an important issue.
The content of the invention
The present invention provides the purposes that a kind of Chinese herbal medicine extract is used to prepare the drug for the treatment of skin disease, the wherein medium-height grass
The raw material for preparing of medicine extract includes Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony.
The present invention also provides a kind of Chinese herbal medicine extracts to be used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the Chinese herbal medicine extract prepare raw material include Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony.
The present invention separately provides a kind of medical composition for slowing down skin disease, including：Herb extract, the wherein Chinese herbal medicine
The raw material for preparing of extract includes Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony；And steroids, the wherein herb extract
There is to reduce side effect caused by the steroids and/or consolidate compared to the steroids is used alone with such is reduced
The effect of effective dose needed for alcohol.
Brief description
Figure 1A is shown, in the class silver bits disease animal model experiment induced in imiquimod (imiquimod, IMQ), control
The skin photo of the mouse of group, control group and four experimental groups.
Figure 1B is shown in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and four realities
Test the gene performance amount of IL-17A, IL-6 of mouse of group, TNF-α and S100A7.
Fig. 2A is shown, in the class silver bits disease animal model experiment of imiquimod induction, control group and three experimental groups
The mouse of (PT-A (100mg) ointment processing group, PT-A-1 (100mg) ointment processing group, PT-A-2 (100mg) ointment processing group)
Skin photo.
Fig. 2 B are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and three realities
Test group (PT-A (100mg) ointment processing group, PT-A-1 (100mg) ointment processing group, PT-A-2 (100mg) ointment processing group)
The furfur of mouse adds rubescent severity scale.
Fig. 3 is shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and experimental group
The skin photo of mouse of (PT-A-DS (100mg/kg) intraperitoneal injection processing group) and the Hematoxylin-eosin of dermatological specimens
(hematoxylin and eosin) coloration result.
Fig. 4 A are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and two realities
Test the skin photo of the mouse of group (PT-A (10mg) ointment processing group and PT-A (100mg) ointment processing group).
Fig. 4 B are shown in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and two realities
Test IL-17A, IL-23 and IL-22 of the mouse of group (PT-A (10mg) ointment processing group and PT-A (100mg) ointment processing group)
Gene performance amount.
Fig. 4 C are shown in the class silver bits disease animal model experiment of imiquimod induction, control group and experimental group (PT-A
(100mg) ointment processing group) mouse immuning tissue dye carried out with CD68, CD4, Neutrophil, Ki-67 and CD31 antibody
The result of color.
Fig. 5 A are shown, dynamic in fluoro- 2,4- dinitrobenzenes (1-fluoro-2,4-dinitrobenzene, the DNFB) inductions of 1-
In object contact atopic dermatitis model experiment, control group, the mouse of positive control group and experimental group (PT-A (50mg) ointment processing group)
The increase thickness of ear.
Fig. 5 B show, in fluoro- 2, the 4- dinitrobenzenes induced animal contact atopic dermatitis model experiments of 1-, control group, just
Control group and the photo of the mouse inflammation partial skin sample of experimental group (PT-A (50mg) ointment processing group) and CD4 immuning tissues
The result of staining analysis.
Fig. 6 A are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and three groups
Experimental group (PT-A (100mg) ointment processing group, Rinderon-V (0.06%, Taiwan salt wild justice) ointment processing group and
Daivonex (0.005%, LEO Pharma) ointment processing group) mouse skin photo.
Fig. 6 B are shown in the class silver bits disease animal model experiment of imiquimod induction, and control group, control group and three groups are real
Test group (PT-A (100mg) ointment processing group, Rinderon-V (0.06%, Taiwan salt wild justice) ointment processing group and
Daivonex (0.005%, LEO Pharma) ointment processing group) IL-17A, IL-6 of mouse, the base of TNF-α and S100A7
Because of performance amount.
Fig. 7 A are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group (IMQ), control group
(IMQ+ mediators) and three experimental groups (IMQ+BD (steroids) ointment processing group, IMQ+BD+PT-A ointment processing groups (25mg) with
Daivobet (LEO Pharma) ointment processing group) mouse skin photo.
Fig. 7 B are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and three realities
Group is tested (at BD (steroids) ointment processing group, BD+PT-A ointment processing groups (25mg) and Daivobet (LEO Pharma) ointment
Reason group) the furfur of mouse add rubescent severity scale.
Fig. 7 C are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and three realities
Group is tested (at BD (steroids) ointment processing group, BD+PT-A ointment processing groups (25mg) and Daivobet (LEO Pharma) ointment
Reason group) mouse skin sample Hematoxylin-eosin (hematoxylin and eosin) coloration result.
Fig. 7 D are shown, in the class silver bits disease animal model experiment of imiquimod induction, control group, control group and three realities
Group is tested (at BD (steroids) ointment processing group, BD+PT-A ointment processing groups (25mg) and Daivobet (LEO Pharma) ointment
Reason group) the result that immuning tissue dyeing is carried out with Ki-67 antibody.
Fig. 8 A-1 and Fig. 8 A-2 display controls group (mediator (vehicle)) and three experimental group (fluocinolone acetonide
(fluocinonide) (0.05%；Middle effect steroids) ointment processing group, fluocinolone acetonide+PT-A (0.25%) ointment processing group (PT-
A is 5 than the weight ratio of fluocinolone acetonide:1), (PT-A is 100 than the weight ratio of fluocinolone acetonide to fluocinolone acetonide+PT-A (5%) ointment processing group:
1), PT-A (5%) ointment processing group and the processing of chloramphenicol propionate (clobetasol propionate) (0.05%) ointment
Group) mouse skin photo.
Fig. 8 B-1 and Fig. 8 B-2 display controls groups (mediator) and three experimental group (fluocinolone acetonide (0.05%；Middle effect class is consolidated
Alcohol) ointment processing group, fluocinolone acetonide+PT-A (0.25%) ointment processing group (PT-A than fluocinolone acetonide weight ratio be 5:1), fluocinolone acetonide
(PT-A is 100 than the weight ratio of fluocinolone acetonide to+PT-A (5%) ointment processing group:1), PT-A (5%) ointment processing group and propionic acid
Clobetasol (0.05%) ointment processing group) mouse dermatological specimens Hematoxylin-eosin coloration result.
Fig. 8 C display controls groups (mediator) and three experimental group (fluocinolone acetonide (0.05%；Middle effect steroids) ointment processing
(PT-A is 5 than the weight ratio of fluocinolone acetonide for group, fluocinolone acetonide+PT-A (0.25%) ointment processing group:1), fluocinolone acetonide+PT-A (5%)
(PT-A is 100 than the weight ratio of fluocinolone acetonide to ointment processing group:1), PT-A (5%) ointment processing group and chloramphenicol propionate
(0.05%) ointment processing group) the rubescent of mouse, the severity scale of furfur and skin thickness.
Fig. 9 A show, control group (mediator) and three experimental groups (PT-A (content 25mg/g) ointment processing group, can stand it is easypro
Emulsifiable paste (CLOBETASOL Cream, mixing emulsifiable paste base chloramphenicol propionate content are 0.25mg/g) processing group and appropriate skin are net
Hydrophilic ointment (TOPSYM Cream, mixing emulsifiable paste base fluocinolone acetonide content are 0.25mg/g) processing group) mouse ear it is thick
Degree.
Fig. 9 B show, control group (mediator) and three experimental groups (PT-A (content 25mg/g) ointment processing group, can stand it is easypro
Emulsifiable paste (CLOBETASOL Cream, mixing emulsifiable paste base chloramphenicol propionate content are 0.25mg/g) processing group and appropriate skin are only close
Water ointment (TOPSYM Cream, mixing emulsifiable paste base fluocinolone acetonide content are 0.25mg/g) processing group) mouse dermatological specimens
Hematoxylin-eosin coloration result.
Figure 10 A show, control group (mediator), control group (Clobetasol) and two groups of experimental group (PT-A (content 25mg/
G) ointment processing group is mixed with PT-A (content 25mg/g) can found easypro emulsifiable paste (CLOBETASOL Cream content 0.25mg/g)
(Clobetasol+PT-A) ointment processing group) mouse ear thickness.
Figure 10 B show, control group (mediator), control group (Clobetasol) and two groups of experimental group (PT-A (content 25mg/
G) ointment processing group is mixed with PT-A (content 25mg/g) can found easypro emulsifiable paste (CLOBETASOL Cream content 0.25mg/g)
(Clobetasol+PT-A) ointment processing group) mouse dermatological specimens Hematoxylin-eosin coloration result.
Figure 11 A show, control group (without any processing), control group (Rinderon-V (0.06%) ointment processing group) and
Experimental group (the skin appearance of the mouse of PT-A (content 25mg/g) ointment processing group.
Figure 11 B show, control group (without any processing), control group (Rinderon-V (0.06%) ointment processing group) and
The Hematoxylin-eosin coloration result of the mouse skin sample of experimental group (PT-A (content 25mg/g) ointment processing group).
Figure 12 shows, the human skin repetitive stimulation of PT-A (content 25mg/g) ointment processing and sensitivity test knot
Fruit.In ethnic group column, C represents Caucasian (Caucasian), and H represents Latin Americans (Hispanic)；In reaction field
In, Dc (Discontinued) means that subject's absence can not be tested；In fraction field, N/A (Not applicable) generations
Table causes fraction that can not calculate since subject is absent.
Embodiment
In one embodiment of this invention, the drug that a kind of Chinese herbal medicine extract is used to prepare treatment skin disease is provided
Purposes.
Above-mentioned skin disease may include autoimmunity related skin complaints or infectious skin disease.And above-mentioned autoimmunity
The example of related skin complaints, it may include, but it is not limited to silver bits disease, allergic dermatitis, Atopic dermatitis etc..
In the purposes for the drug for being used to prepare treatment skin disease in the Chinese herbal medicine extract of the present invention, said herbal medicine extraction
Taking the raw material for preparing of object may include Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony.In one embodiment, said herbal medicine extract
The raw material for preparing be made of Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony.
The example of above-mentioned Radix Glycyrrhizae may include licorice, honey-fried licorice root etc., but not limited to this.And above-mentioned radix bupleuri then may include, but
It is not limited to, raw Bupleurum Chinese, Gao Shi radix bupleuri etc..Above-mentioned radix scutellariae may include such as withered and yellow a kind of reed mentioned in ancient books, radix scutellariae, but not limited to this.On also,
Stating the example of Schisandra chinensis then may include, but be not limited to, fructus schisandrae, kadsura longepedunculata etc..In addition, above-mentioned Chinese herbaceous peony then may include, but
It is not limited to the radix paeoniae rubrathe, Radix Paeoniae Alba, tree peony etc..
Preparing in raw material in said herbal medicine extract again, Radix Glycyrrhizae, radix bupleuri, radix scutellariae, the weight ratio of Schisandra chinensis and Chinese herbaceous peony
It can be about 1-5：1-5：1-5：1-5：1-5, but not limited to this.In one embodiment, it is former in the preparation of said herbal medicine extract
In material, Radix Glycyrrhizae, radix bupleuri, radix scutellariae, the weight ratio of Schisandra chinensis and Chinese herbaceous peony can be about 1：1：1：1：1.
And obtain the mode of said herbal medicine extract there is no particular restriction, it can be various known to the art at present
Mode obtains.In one embodiment, can be obtained by the extracting process comprised the following steps：First raw material is prepared by foregoing
In Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis mix to form raw mixture with Chinese herbaceous peony, then, by raw mixture with solvent into
Row extraction processing procedure.In another embodiment, then can be obtained by another extracting process comprised the following steps：It first will be above-mentioned
It prepares the Radix Glycyrrhizae in raw material, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony and is extracted to generate Radix Glycyrrhizae extract, bavin respectively with solvent
Then, above-mentioned Radix Glycyrrhizae extract, radix bupleuri are extracted for Hu extract, radix scutellariae extract, Schisandra chinensis extract and Chinese herbaceous peony extract
Object, radix scutellariae extract, Schisandra chinensis extract are mixed with Chinese herbaceous peony extract.
And it is above-mentioned to carry out extraction processing procedure solvent may include water or organic solvent, but not limited to this.Above-mentioned is organic
Solvent may include, but be not limited to alcohols, ketone, acids, esters etc..Also, the example of above-mentioned alcohols may include methanol, ethyl alcohol etc.,
But not limited to this.In one embodiment, above-mentioned solvent can be ethyl alcohol.In a specific embodiment, above-mentioned solvent can be 30% second
Alcohol.In another specific embodiment, above-mentioned solvent can be 75% ethyl alcohol.
In one embodiment, preparing in raw material in said herbal medicine extract, Radix Glycyrrhizae is licorice, radix bupleuri is northern bavin
Recklessly, radix scutellariae is withered and yellow a kind of reed mentioned in ancient books, Schisandra chinensis is fructus schisandrae and Chinese herbaceous peony is the radix paeoniae rubrathe.Above-mentioned licorice, Bupleurum Chinese, withered and yellow a kind of reed mentioned in ancient books, Chinese Magnoliavine
The weight ratio of son and the radix paeoniae rubrathe can be about 1：1：1：1：1, but not limited to this.Also, in a specific embodiment, said herbal medicine extraction
The raw material for preparing of object includes licorice, Bupleurum Chinese, withered and yellow a kind of reed mentioned in ancient books, fructus schisandrae and the radix paeoniae rubrathe, and licorice, Bupleurum Chinese, withered and yellow a kind of reed mentioned in ancient books, north
The weight ratio of Schisandra chinensis and the radix paeoniae rubrathe can be about 1：1：1：1：1, and said herbal medicine extract system passes through the extraction that comprises the following steps
Method is taken to be obtained：The licorice prepared in raw material, the Bupleurum Chinese, the withered and yellow a kind of reed mentioned in ancient books, the fructus schisandrae are mixed with the radix paeoniae rubrathe
To form raw mixture, raw mixture is subjected to extraction processing procedure with solvent afterwards.Again in this specific embodiment, the use
Can be ethyl alcohol with the solvent for carrying out extraction processing procedure, such as 30% ethyl alcohol, 75% ethyl alcohol etc..
It is prepared in the purposes for the drug for being used to prepare treatment skin disease in the Chinese herbal medicine extract of the invention described above
Treat skin disease drug can be Topical dosage forms or Parenteral, but not limited to this.In one embodiment, it is made
The drug of standby treatment skin disease is Topical dosage forms, and the example of this Topical dosage forms may include, but is not limited to soft
Cream, emulsion, liquor, gel etc..
With the drug of the treatment skin disease prepared by above-mentioned any Chinese herbal medicine extract, the safety with height
Property, and ill-effect will not be generated to individual.Also, the treatment skin disease prepared by with above-mentioned any Chinese herbal medicine extract
Drug, for treating various skin diseases, have effects that it is excellent, especially for the skin disease with inflammation symptom,
Slow down inflammation effect with excellent.
In another embodiment, the drug for the treatment of skin disease is used to prepare for the Chinese herbal medicine extract of the invention described above
Purposes for, can further include by foregoing any Chinese herbal medicine extract be used to prepare together with steroids treatment skin disease medicine
The purposes of object.In this embodiment, the weight ratio of Chinese herbal medicine extract and steroids can be about 5:1-200:1, but not limited to this.
In a specific embodiment, the weight ratio of Chinese herbal medicine extract and steroids can be about 83:1.And in another specific embodiment,
The weight ratio of Chinese herbal medicine extract and steroids can be about 5:1.And in another specific embodiment, Chinese herbal medicine extract and class
The weight ratio of sterol can be about 100:1.
And above-mentioned steroids can be any steroids for being suitable for skin treating, may be, for example, dexamethasone
(dexamethasone), fluorometholone (fluorometholone), medrysone (medrysone), betamethasone
(betamethasone), triamcinolone (triamcinolone), prednisone (prednisone), prednisolone
(prednisolone), hydrocortisone (hydrocortisone) etc., but not limited to this.
Also, in the above-mentioned drug that foregoing any Chinese herbal medicine extract is used to prepare to treatment skin disease together with steroids
Purposes embodiment in, the drug of prepared treatment skin disease similarly can be Topical dosage forms or Formulations for systemic administration agent
Type, but not limited to this.In a specific embodiment, the drug of prepared treatment skin disease is Topical dosage forms, and this
The example of Topical dosage forms may include, but be not limited to ointment, emulsion, liquor, gel etc..
As the drug of the treatment skin disease prepared by any of the above-described kind of Chinese herbal medicine extract collocation steroids, for controlling
Various skin diseases are treated, have effects that excellent, especially for the skin disease with inflammation symptom, there is excellent slow down
Inflammation effect.Also, in this drug, herb extract can have the work(for reducing side effect caused by arranged in pairs or groups steroids
Effect and/or compared to required effective dose when this steroids is used alone, by needed for herb extract this steroids of arranging in pairs or groups
Effective dose is minimized.
In another embodiment of the present invention, a kind of Chinese herbal medicine extract is provided and is used to prepare improvement with steroid therapy skin
The purposes of the drug of the side effect of skin disease.
Above-mentioned steroids can be any steroids for being suitable for skin treating.And it is suitable for the steroids of skin treating
Example then may include, but be not limited to can dexamethasone, fluorometholone, medrysone, betamethasone, triamcinolone, prednisone, sprinkle Buddhist nun
Song Long, hydrocortisone etc..
And above-mentioned skin disease may include autoimmunity related skin complaints or infectious skin disease.And above-mentioned exempt from self
The example of epidemic disease related skin complaints, it may include, but it is not limited to silver bits disease, allergic dermatitis, Atopic dermatitis etc..
Also, the above-mentioned side effect with steroid therapy skin disease it is meant that during with steroid therapy skin disease possibility
Any unfavorable condition or state triggered, such as thinning of skin and/or blood vessel dilatation etc., but not limited to this.
Also, improvement is used to prepare with the medicine of the side effect of steroid therapy skin disease for Chinese herbal medicine extract of the present invention
Can be that front Chinese herbal medicine extract is used to prepare treatment skin disease in the Chinese herbal medicine extract described in this for the purposes of object
Any Chinese herbal medicine extract mentioned in the relevant paragraph of the purposes of drug, therefore do not repeat to repeat then at this.
In addition, the Chinese herbal medicine extract in the invention described above is used to prepare improvement with the pair work of steroid therapy skin disease
In the purposes of drug, prepared drug can be Topical dosage forms or Parenteral, but not limited to this.It is real one
Apply in example, prepared drug is Topical dosage forms, and the example of this Topical dosage forms may include, but be not limited to ointment,
Emulsion, liquor, gel etc..
In the present invention again another embodiment, a kind of medical composition for slowing down skin disease is provided.
Above-mentioned skin disease may include autoimmunity related skin complaints or infectious skin disease.And above-mentioned autoimmunity
The example of related skin complaints, it may include, but it is not limited to silver bits disease, allergic dermatitis, Atopic dermatitis etc..
The medical composition that the present invention slows down skin disease may include, but be not limited to Chinese herbal medicine extract and steroids.
The Chinese herbal medicine extract for slowing down the medical composition of skin disease and being included of the present invention can be that front Chinese herbal medicine extracts
Object is taken to be used to prepare any Chinese herbal medicine extract mentioned in the relevant paragraph of the purposes for the drug for slowing down skin disease, therefore
It does not repeat to repeat then at this.
And the steroids for slowing down the medical composition of skin disease and being included of the present invention, then it can be suitable for skin to be any
The steroids of skin treatment.Being suitable for the example of the steroids of skin treating may include, can dexamethasone, fluorometholone, medrysone,
Betamethasone, triamcinolone, prednisone, prednisolone, hydrocortisone etc., but not limited to this.
In the medical composition of the treatment skin disease of the present invention, the content of Chinese herbal medicine and steroids has no special limit
System, as long as the medical composition formed has effects that treat skin disease.Said herbal medicine extract and steroids
Weight ratio can be about 5:1-200:1, but not limited to this.In one embodiment, the weight ratio of Chinese herbal medicine extract and steroids
It can be about 83:1.In another embodiment, the weight ratio of Chinese herbal medicine extract and steroids can be about 5:1.And in another reality
It applies in example, the weight ratio of Chinese herbal medicine extract and steroids can be about 100:1.
The medical composition for slowing down skin disease of the present invention can be Topical dosage forms or Parenteral, but unlimited
In this.In one embodiment, the medical composition for slowing down skin disease of the invention, and the example of this Topical dosage forms can wrap
It includes, but is not limited to ointment, emulsion, liquor, gel etc..
In another embodiment, the medical composition of the treatment skin disease of the invention described above can be further included and can pharmaceutically connect
Mediator, carrier or the salt received.
Pharmaceutically acceptable mediator can be used as the diluent, dispersant or carrier of active ingredient.It is pharmaceutically acceptable
Mediator may include the material often used in skin nursing products, such as water, liquid or solid softening agent, silicone oil, emulsifier, molten
Agent, wetting agent, thickener, powder, propellant and analog.
Mediator can account for the 80-99.9wt% of above-mentioned composition, be preferably 85-95wt%, and can be in no other adjuvants
In the presence of form composition remaining part.
Also, aforementioned composition can also further include other special skin benefits activators, such as sun-screening agent and skin lightening dose.
Mediator can also further comprise the adjuvant of the class such as antioxidant, fragrance, opacifier, preservative, colorant and buffer solution.
Include in addition, foregoing all compositions can all be fabricated to a skin varniss pattern in an embodiment, but it is unlimited
In, emulsion, paste, gel, spray, toner, shampoo or curtain this etc..In general, skin spray can be copolymerized by spray form
Object is formed, for example, polyvinylpyrrolidone, vinyl acetate and the like, and it can have the function of toner.Skin coagulates
The preparation method of glue is similar with spray, but it is gelatinous and the presence without ethyl alcohol, can be attached on skin.Skin curtain this for profit
Foam is discharged with pressure.Skin cream is a hydrophobicity or hydrophily emulsion, paste, gel, emollient, spray, paint, skin
Opsonic water, shampoo or curtain this.In addition, can more add suitable composition to skin cream, this composition additionally added includes all
Intellectual circle, wax, lanolin, silicon, micro- fat body, vegetables, mineral oil, plasticizer, fragrance, preservative, permeation enhancers, pH adjuster or
Other are suitable for the composition of local skin.This wettable skin of additional composition, stabilizing active compound increase aforementioned combinatorial
The contact of object-skin, the concentration of regional area, the release of control composition.
Foregoing pharmaceutically acceptable carrier may include, but be not limited to solvent, scattered matchmaker (dispersion medium),
Mantle (coating), antibacterial and antifungal agents and isosmoticity and absorption delay (absorption delaying) reagent etc.
Compatible person is given with pharmacy.For different administering modes, pharmaceutical compositions are configured to dosage form using conventional method
(dosage form)。
It also, above-mentioned pharmaceutically acceptable salt class may include, but is not limited to salt and includes inorganic cation, for example, alkali is golden
Belong to salt, such as sodium, potassium or ammonium salt, alkaline earth gold race salt, such as magnesium, calcium salt, the salt containing divalent or quadrivalent cation, such as zinc, aluminium
Or zirconates.In addition or it is organic salt, such as dicyclohexyl amine salt, methyl-D-glucosamine, amidates, such as smart ammonia
Acid, lysine, histidine, amide glutaminate.
Medical composition of the present invention administration can it is parenteral, oral, via sucking spraying (inhalation spray) or
By way of being implanted into reservoir (implanted reservoir).It is parenteral to may include to embrocate affected part, subcutaneous
(subcutaneous), intracutaneous (intracutaneous), intravenous (intravenous), intramuscular
(intramuscular), in intra-articular (intraarticular), artery (intraarterial), synovial bursa (chamber)
(intrasynovial), (intrasternal) in breastbone, subarachnoid space (intrathecal), in disease location
(intralesional) injection and perfusion technique.
The form for the local application's ingredient embrocated may include ointment, emulsion, liquor, gel etc., but not limited to this.
The form of Oral compositions may include, but be not limited to, lozenge, capsule, emulsion (emulsions), aqueous suspension
(aqueous suspensions), dispersion liquid (dispersions) and solution.
Any medical composition for slowing down skin disease of the invention described above, for slowing down various skin diseases, all has
There is the effect of excellent, especially for the skin disease with inflammation symptom, have and excellent slow down and/or treat chafing
Effect.Also, in this medical composition, herb extract can have the work(for reducing side effect caused by arranged in pairs or groups steroids
Effect and/or compared to required effective dose when this steroids is used alone, by needed for herb extract this steroids of arranging in pairs or groups
Effective dose is minimized.
Embodiment
A. the preparation of various experiment extracts
1. externally-applied ointment dosage form
(1) withered and yellow a kind of reed mentioned in ancient books, Bupleurum Chinese, licorice, the radix paeoniae rubrathe and the fructus schisandrae compound medicinal material extracted by 30% ethanol solution
Extract, radix scutellariae folk prescription extract, radix bupleuri folk prescription extract and radix scutellariae and radix bupleuri compound medicinal material extract
By the Chinese herbal medicine formula of following four difference compound and folk prescription (1) radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and Chinese Magnoliavine
Sub- compound medicinal material (weight ratio 1:1:1:1:1) (PT-A), (2) radix scutellariae folk prescription (SR), (3) radix bupleuri folk prescription (BR) and (4) radix scutellariae
And radix bupleuri compound medicinal material (weight ratio 1:1) (SR+BR) carries out following extraction procedures respectively：
By Chinese herbal medicine formula it is small with the 30% ethanol solution heating extraction 1 of 10 times of weight when, to obtain the first extract liquor.It will
First extract liquor takes out, then the aforementioned formula through extraction is small equally with the 30% ethanol solution reheating extraction 1 of 10 times of weight
When, to obtain second of extract liquor.Then, extract liquor will mix twice.The extract liquor of gained was carried out with 100mesh sieves
Filter, then through being concentrated under reduced pressure, be freeze-dried afterwards.
By Chinese herbal medicine formula freeze-dried powder (1g) and 95% alcohol (1.4g), polyethylene glycol 400 (10g), poly- second two
Alcohol 4000 (4.5g) and the deionized water of Crodaret (0.15g) and high-purity (deionized water)
(2.95ml) is heated to 60 DEG C and is mixed into uniformly, to be fabricated to externally-applied ointment dosage form.
That is, four kinds of ointment set forth below is obtained：(1) radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and fructus schisandrae compound medicinal material (weight
Measure ratio 1:1:1:1:1) ointment of (PT-A), the ointment of (2) radix scutellariae folk prescription (SR), the ointment of (3) radix bupleuri folk prescription (BR) and (4)
Radix scutellariae and radix bupleuri compound medicinal material (weight ratio 1:1) ointment of (SR+BR).
(2) each folk prescription medicinal material is extracted by 30% ethanol solution respectively and each folk prescription extract is mixed to obtained mixing
Extract
By following five kinds different folk prescription Chinese herbal medicines, radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony, fructus schisandrae folk prescription carry out respectively with
Lower extraction processing procedure：
By single Chinese herbal medicine it is small with the 30% ethanol solution heating extraction 1 of 10 times of weight when, to obtain the first extract liquor.It will
First extract liquor takes out, then the aforementioned formula through extraction is small equally with the 30% ethanol solution reheating extraction 1 of 10 times of weight
When, to obtain second of extract liquor.Then, extract liquor will mix twice.The extract liquor of gained was carried out with 100mesh sieves
Filter.
That is, radix scutellariae folk prescription, Bupleurum Chinese folk prescription, Radix Glycyrrhizae folk prescription, Chinese herbaceous peony folk prescription, the filtrate of fructus schisandrae folk prescription are obtained respectively.
Foregoing five kinds of filtrate is mixed, to obtain radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae folk prescription, Chinese herbaceous peony and the mixing filtrate of fructus schisandrae
(PT-A-1), then by it through being concentrated under reduced pressure, it is freeze-dried afterwards.
Freeze-dried powder (1g) and 95% alcohol (1.4g), polyethylene glycol 400 (10g), Macrogol 4000 (4.5g),
60 DEG C are heated to the deionized water (2.95ml) of Crodaret (0.15 gram) and high-purity to be mixed into uniformly,
It is fabricated to ointment dosage form.
That is, the extraction liquid mixture of radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and fructus schisandrae that 30% ethyl alcohol extracts is obtained
(PT-A-1) ointment.
(3) radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and the fructus schisandrae compound medicinal material extracted by 75% ethanol solution extracts
Object
Radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and fructus schisandrae compound are heated into extraction with 75% ethanol solution of 10 times of weight
1 it is small when, to obtain the first extract liquor.First extract liquor is taken out, then by the aforementioned formula through extraction equally with 10 times of weight
When 75% ethanol solution reheating extraction 1 is small, to obtain second of extract liquor.Then, extract liquor will mix twice.By gained
Extract liquor is filtered with 100mesh sieves, then through being concentrated under reduced pressure, is freeze-dried afterwards.
By freeze-dried powder (1g) and 95% alcohol (1.4g), polyethylene glycol 400 (10g), Macrogol 4000
The deionized water (2.95ml) of (4.5g) and Crodaret (0.15g) and high-purity is heated to 60 DEG C and mixes
To uniform, to be fabricated to externally-applied ointment dosage form.
That is, radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and the fructus schisandrae compound medicinal material (weight ratio 1 of 75% ethyl alcohol extraction are obtained:
1:1:1:1) ointment of (PT-A-2).
(4) steroids ointment
By dipropium dipropionate (Betamethasone dipropionate) powder (0.006g), 95% alcohol
(1.4g), polyethylene glycol 400 (10g), Macrogol 4000 (4.5g) and Crodaret (0.15g) and high-purity
Deionization (DI) water (3.944ml) of degree is heated to 60 DEG C and is mixed into uniformly, is fabricated to externally-applied ointment dosage form (BD).
(5) the mixing ointment of radix scutellariae, Bupleurum Chinese, Radix Glycyrrhizae, Chinese herbaceous peony and fructus schisandrae compound medicinal material and steroids
By PT-A dried powders (0.5g), dipropium dipropionate powder (0.006g), 95% alcohol (1.4g), poly- second two
Alcohol 400 (10g), Macrogol 4000 (4.5g) and the deionized water of Crodaret (0.15g) and high-purity
(3.444ml) is heated to 60 DEG C and is mixed into uniformly, is fabricated to externally-applied ointment dosage form (PT-A+BD).
2. liquid dosage form
By 70mg PT-A dried powders with 7ml solvents (10%DMSO and 90% tricaprylin (glyceryl
Trioctanoate liquid dosage form, concentration 10mg/ml)) are allocated as.
B. experimental method and result
1. embodiment 1
Compound reduces the class silver bits disease animal model skin disease that imiquimod (imiquimod, IMQ) induces
Efficacy assessment
Influence of the extract for reduction skin disease is assessed using the class silver bits disease animal model of imiquimod induction.
Implementation step is as follows：
First by Balb/c mouse (6~8 week old) back hair cutting, and mouse is divided into control group, control group and four
Group experimental group, wherein four groups of experimental groups are respectively PT-A (100mg) ointment processing group, SR (100mg) ointment processing group, BR
(100mg) ointment processing group, SR+BR (100mg) ointment processing group.
Do not give mouse any processing in control group；Control group is then by the imiquimod cream (Aldara of 62.5mg；3M
Pharmaceuticals mouse back) is applied to, is administered once per day for the treatment of imiquimod cream, is continuously given six days, it is small to induce
Mouse skin silver bits disease symptom generates；And in four groups of experimental group, then the imiquimod cream of 62.5mg is first applied to mouse
Back then to each group difference partial smearing test ointment (100mg), is administered once per day for the treatment of imiquimod cream and each experimental group
Ointment is continuously given six days.
The degree of back part of animal skin disease is assessed afterwards, including projects such as rubescent, furfurs, and is taken a picture.Animal is sacrificed
Afterwards, its back inflamed sites skin is taken to carry out the gene performance amount detection of tissue, including IL-17A, IL-6, TNF-α, S100A7
Deng.As a result as shown in Figure 1A and Figure 1B.
Figure 1A shows, control group compared with control group after imiquimod is given, can significantly cause mouse skin it is rubescent with
Furfur phenomenon, however in experimental group while give imiquimod with after PT-A, then mouse skin disease phenomenon can be mitigated.But
Other three groups of experimental groups, which have no, improves mouse skin disease phenomenon (Figure 1A).
Figure 1B is shown, in gene performance amount, compared to control group, IL-17A, IL-6 of control group, TNF-α and
S100A7 is significantly increased situation, however in the tissue for smearing PT-A ointment animals, gene performance amount then has becoming for decline
Gesture assigns significant difference (* p wherein being compared with the performance amount and control group of IL-6, TNF-α and S100A7<0.05, * * * p<
0.001)。
2. embodiment 2
Compound extracts the effect of class silver bits disease animal model skin disease of the mode to reducing imiquimod induction
Assessment
Main experimental methods are identical with embodiment 1 (not setting control group again), and experimental group is then changed to PT-A
Three groups of experiments of (100mg) ointment processing group, PT-A-1 (100mg) ointment processing group, PT-A-2 (100mg) ointment processing group
Group, to assess the influence in a manner of extraction to effect.
Each experimental group is administered once per day for the treatment of imiquimod cream and experiment ointment (100mg), continuously gives six days.
The degree of back part of animal skin disease is assessed afterwards, including projects such as rubescent, furfurs, and is added according to furfur rubescent tight
Weight degree gives 0-8 points (most serious person gives 8 points, and asymptomatic person gives 0 point) and takes a picture.As a result as Fig. 2A and Fig. 2 B are shown
Show.
It is understood according to Fig. 2A and Fig. 2 B, compared with rubescent and furfur phenomenon of the control group after imiquimod is given, experiment
Imiquimod is given while in group with mouse skin disease phenomenon (Fig. 2A) after 100mg PT-A, can be mitigated, and its improvement is de-
Considering situation to be worth doing has significant difference (Fig. 2 B), and PT-A-1 can not significantly improve mouse skin disease condition with PT-A-2 groups.
3. embodiment 3
Intraperitoneal injection PT-A-DS assesses the effect of small muroid silver bits disease skin disease
The class silver bits disease animal model induced by imiquimod assesses influences of the PT-A of the present invention for skin disease.Its
Implementation steps are as follows：
First by Balb/c mouse (6~8 week old) back hair cutting, and by mouse be divided into control group, control group and
Experimental group.
Do not give mouse any processing in control group；Control group is by 62.5mg (Aldara containing imiquimod cream；3M
Pharmaceuticals mouse back) is applied to, is administered once per day for the treatment of imiquimod cream, is continuously given six days small to induce
Mouse skin silver bits disease symptom generates；And the imiquimod cream of 62.5mg is then applied to mouse back by experimental group, is then passed through
PT-A-DS (100mg/kg) is given in intraperitoneal injection, and (solvent is 10%DMSO and 90% tricaprylin (glyceryl
Trioctanoate)), imiquimod cream and PT-A-DS (100mg/kg) are administered once per day for the treatment of, is continuously given six days.
Mouse is sacrificed afterwards, and its inflamed sites skin removed and is soaked in 4% formaldehyde (formaldehyde) and is consolidated
It is fixed, then sample is dyed with rip cutting into after 6 μ m thicks, then with Hematoxylin-eosin (hematoxylin and eosin), with
Skin disease degree is assessed, including epithelial thickness, parakeratosis or hyperplasia etc..The results are shown in Figure 3.
Fig. 3 shows that control group after imiquimod is given, can significantly cause mouse skin and send out compared with control group
Red, furfur and epithelium thickening phenomenon, however, giving imiquimod simultaneously in experimental group with that after intraperitoneal injection PT-A, then can subtract
Light mouse skin disease phenomenon.
4. embodiment 4
The effect of PT-A is to reducing small muroid silver bits disease skin disease is assessed
In the present embodiment, the class silver induced by imiquimod considers disease animal model to be worth doing to assess PT-A ointment for skin disease
The influence of disease.Implementation step is as follows：
First by Balb/c mouse (6~8 week old) back hair cutting, and by mouse be divided into control group, control group and
Two groups of experimental groups, wherein two groups of experimental groups are respectively PT-A (10mg) ointment processing group and PT-A (100mg) ointment processing group.
Do not give mouse any processing in control group；Control group is then by the imiquimod cream (Aldara of 62.5mg；3M
Pharmaceuticals mouse back) is applied to, is administered once per day for the treatment of imiquimod cream, is continuously given six days, it is small to induce
Mouse skin silver bits disease symptom generates；And the imiquimod cream of 62.5mg is then applied to mouse back by experimental group, it is then local
PT-A (10mg and 100mg) is smeared, imiquimod cream and PT-A ointment is administered once per day for the treatment of, continuously gives six days.
The degree of back part of animal skin disease is assessed afterwards, including projects such as rubescent, furfurs.After animal is sacrificed, it is taken
Back inflamed sites skin carries out the gene performance amount detection of tissue, including IL-17A, IL-23, IL-22 etc., and by its inflammation
Area skin, which is removed, to be soaked in 4% formaldehyde and is fixed, then by sample with rip cutting into after 6 μ m thicks, then respectively with CD68,
CD4, Neutrophil, Ki-67 and CD31 antibody carry out immuning tissue's dyeing, to assess the leaching of the immunocyte at skin disease position
Phenomena such as profit, hyperplasia and angiogenesis.As a result as shown in Fig. 4 A, Fig. 4 B and Fig. 4 C.
Fig. 4 shows that control group after imiquimod is given, can significantly cause mouse back pachyderma compared with control group
Phenomenon, however in experimental group while give imiquimod with after 100mg PT-A, then mouse skin disease phenomenon can be mitigated.
In gene performance amount, compared to control group, IL-17, IL-23 and IL-22 of control group are significantly increased feelings
Shape, however in the tissue for smearing PT-A ointment animals, gene performance amount then has a declining tendency；It is compared down with control group,
The performance amount of IL-17, IL-23 and IL-22 of 100mg PT-A groups reach significant difference, and the IL-22 of 100mg PT-A groups
Performance amount then have significant difference (* p<0.05, * * p<0.01) (Fig. 4 B).
In addition, give imiquimod compared with control group, in experimental group while, gives imiquimod and 100mg
After PT-A, the performance amount of mouse skin CD68, CD4, Neutrophils, Ki-67 and CD31 or number (Fig. 4 C) can be reduced.
5. embodiment 5
PT-A is to reducing fluoro- 2,4- dinitrobenzenes (1-fluoro-2,4-dinitrobenzene, the DNFB) induced animals of 1-
Contact the effect of atopic dermatitis
In the present embodiment, atopic dermatitis model is contacted by fluoro- 2, the 4- dinitrobenzenes induced animals of 1- to assess PT-A pairs
Reduce the influence of contact skin disease.Implementation step is as follows：
C57BL/6 mouse are divided into control group, positive control group and experimental group to carry out different disposal.It will provide first
0.5%DNFB connects in each group mouse (the coating portion of control group, positive control group and experimental group is respectively abdomen, ear and ear)
Continue after giving five days, carry out following tests.
In control group, for 0.2%DNFB is applied to mouse web portion；It in positive control group, will face grand
(Rinderon) (0.5mg/g) is applied to mouse ear；In experimental group, then PT-A (50mg) ointment is applied to mouse ear
Piece.
After above out of the ordinary processing is when 18 is small, the anaphylactoid degree of animal contact is reevaluated, and is sacrificed in animal
Afterwards, the CD4 immuning tissues staining analysis of inflamed sites skin is carried out.As a result as shown in Fig. 5 A and Fig. 5 B.
Fig. 5 A and Fig. 5 B are shown, fluoro- 2, the 4- dinitrobenzenes of 1- are given compared with control group, after experimental group gives PT-A,
Mouse skin thickened degree can be reduced and CD4 infiltration numbers, the result of the test that Rinderon is given with positive control group are close.
6. embodiment 6
Compared with the effect of PT-A muroid silver small with the reduction of commercial product considers disease skin disease to be worth doing assessment
In the present embodiment, the class silver induced by imiquimod considers disease animal model to be worth doing to assess the work(of PT-A and commercial product
Effect compares.Implementation steps are as follows：
First by Balb/c mouse (6-8 week old) back hair cutting, and mouse is divided into control group, control group and three
Group experimental group, wherein three groups of experimental groups are respectively PT-A (100mg) ointment processing group, (0.06%, Taiwan salt is wild by Rinderon-V
Justice) ointment processing group and Daivonex (0.005%, LEO Pharma) ointment processing group.
Do not give mouse any processing in control group；Control group is then by 62.5mg (Aldara containing imiquimod cream；3M
Pharmaceuticals mouse back) is applied to, is administered once per day for the treatment of imiquimod cream, is continuously given six days, it is small to induce
Mouse skin silver bits disease symptom generates；And 62.5mg imiquimod creams are then applied to mouse back by experimental group, it is then local to apply
Test ointment is smeared, imiquimod cream and test ointment is administered once per day for the treatment of, continuously gives six days.
The degree of back part of animal skin disease is assessed afterwards, including projects such as rubescent, furfurs, and is taken a picture.Animal is sacrificed
Afterwards, its back inflamed sites skin is taken to carry out the gene performance amount detection of tissue, including IL-17A, TNF-α, IL-6, S100A7
Deng.As a result as shown in figs. 6 a and 6b.
Fig. 6 A show, control group compared with control group after imiquimod is given, can significantly cause mouse skin it is rubescent with
Furfur phenomenon, however in experimental group while give imiquimod with after PT-A or Rinderon, then mouse skin can be mitigated
Disease phenomenon.
Fig. 6 B, in gene performance amount, compared to control group, the IL-17A of control group, TNF-α, IL-6 and S100A7 are equal
Situation is significantly increased, however in the tissue for smearing PT-A or Rinderon ointment animals, gene performance amount then has decline
Trend assigns significant difference (* p wherein being compared with the performance amount and control group of IL-6, TNF-α and S100A7<0.05, * * p<
0.01, * * * p<0.001).Though Daivonex groups are compared down with control group up to significance difference in TNF-α and the performance amount of S100A7
It is different, but be not apparent from improving mouse skin furfur phenomenon.
7. embodiment 7
PT-A merges use with steroids ointment and assesses reducing the effect of small muroid silver considers disease skin disease to be worth doing
The class silver bits disease animal model induced by imiquimod adds steroids ointment for skin disease to assess PT-A
The influence of disease.Implementation step is as follows：
First by Balb/c mouse (6-8 week old) back hair cutting, and mouse is divided into control group, control group and three
Group experimental group, three groups of experimental groups are respectively BD (steroids) ointment processing group, BD+PT-A ointment processing group (weights of the PT-A than BD
Amount is than being 83:1) with Daivobet (LEO Pharma) ointment processing group.Every animal of each group is per treatment to smear 25mg ointment.
By the imiquimod cream (Aldara of 62.5mg in control group；3M Pharmaceuticals) it is applied to the mouse back of the body
Portion, is administered once per day for the treatment of imiquimod cream, continuously gives six days, is generated with inducing mouse skin silver bits disease symptom；Control group
The imiquimod cream of 62.5mg is then applied to mouse back, then partial smearing ointment base；Experimental group is then by 62.5mg
Imiquimod cream be applied to mouse back, then partial smearing test ointment, be administered once per day for the treatment of imiquimod cream with
Ointment is tested, is continuously given six days.
The degree of back part of animal skin disease is assessed afterwards, including the projects such as furfur, rubescent, and is added according to furfur rubescent
Severity gives 0-8 points (most serious person gives 8 points, and asymptomatic person gives 0 point) and takes a picture.After animal is sacrificed, sent out
Scorching area skin, which is removed, to be soaked in 4% formaldehyde and is fixed, then by sample with rip cutting into after 6 μ m thicks, then with haematoxylin-she
Red colouring to assess skin disease degree, including epithelial thickness, parakeratosis or hyperplasia etc., and is carried out with Ki-67 antibody respectively
Immuning tissue dyes, to assess the hyperplasia phenomenon at skin disease position.As a result as shown in Fig. 7 A to Fig. 7 D.
Understood according to Fig. 7 A to Fig. 7 D, control group after imiquimod is given, can significantly cause mouse skin occur it is rubescent,
Furfur and epithelium thickening phenomenon (Fig. 7 A and Fig. 7 C), however imiquimod is given simultaneously in experimental group with after BD+PT-A, then may be used
Mitigate mouse skin disease phenomenon, including significantly mitigating furfur and redness phenomenon (Fig. 7 B), compared with control group and assign significance difference
Different (* p<0.05, * * p<0.01, * * * p<0.001) epithelium, is reduced to thicken (Fig. 7 C) and reduce Ki-67 performances amount (Fig. 7 D),
Mouse skin disease phenomenon can not then be significantly improved by reviewing BD and Daivobet experimental groups.
Embodiment 8
PT-A merges with middle effect steroids ointment considers disease skin disease to be worth doing using with strong ferment steroids to reducing small muroid silver
Effect compares
The class silver bits disease animal model induced by imiquimod adds middle effect steroids ointment for skin to assess PT-A
The influence of skin disease.Implementation step is as follows：
First by C57BL/6 mouse (6~8 week old) back hair cutting, and by mouse be divided into control group, control group and
Six groups of experimental groups, six groups of experimental groups are respectively fluocinolone acetonide (fluocinonide) (0.05%；Middle effect steroids) ointment processing group,
(PT-A is 5 than the weight ratio of fluocinolone acetonide to fluocinolone acetonide+PT-A (0.25%) ointment processing group:1), fluocinolone acetonide+PT-A (5%) ointment
(PT-A is 100 than the weight ratio of fluocinolone acetonide to processing group:1), PT-A (5%) ointment processing group and chloramphenicol propionate
(clobetasol propionate) (0.05%) ointment processing group.Every animal of each group is per treatment to smear 25mg ointment.
By the imiquimod cream (Aldara of 62.5mg in control group；3M Pharmaceuticals) it is applied to the mouse back of the body
Portion, is administered once per day for the treatment of imiquimod cream, continuously gives six days, is generated with inducing mouse skin silver bits disease symptom；Control group
The imiquimod cream of 62.5mg is then applied to mouse back, then partial smearing ointment base；Experimental group is then by 62.5mg
Imiquimod cream be applied to mouse back, then the test ointment of partial smearing 25mg, is administered once per day for the treatment of imiquimod
Emulsifiable paste and test ointment, continuously give six days.
The degree of back part of animal skin disease is assessed afterwards, including three items such as furfur, rubescent, furfur and skin thickness
Mesh, and give 0-12 points (most serious person gives 12 points, and asymptomatic person gives 0 point) simultaneously according to above three other severity
Photograph.After animal is sacrificed, its inflamed sites skin is removed and is soaked in 4% formaldehyde and is fixed, then by sample with rip cutting
It is dyed into after 6 μ m thicks, then with Hematoxylin-eosin, to assess skin disease degree, including epithelial thickness, parakeratosis or increasing
It is raw etc..As a result as shown in Fig. 8 A-1, Fig. 8 A-2, Fig. 8 B-1, Fig. 8 B-2 and Fig. 8 C.
Understand that, compared to control group, experimental group gives fluorine simultaneously according to Fig. 8 A-1 and Fig. 8 A-2 and Fig. 8 B-1 and Fig. 8 B-2
Easily after+PT-A, mouse skin disease phenomenon can be mitigated, including mitigating rubescent, furfur and epithelium thickening phenomenon (Fig. 8 A-1 and figure
8A-2 and Fig. 8 B-1 and Fig. 8 B-2), and compared with control group, display significant difference (* * p<0.01, * * * p<0.001) (Fig. 8 C).
Wherein, compared to fluocinolone acetonide processing group, the fluocinolone acetonide+PT-A of experimental group can improve the improvement degree of mouse skin disease, including
Mitigate rubescent, furfur and epithelium thickening phenomenon (Fig. 8 A-1 and Fig. 8 A-2 and Fig. 8 B-1 and Fig. 8 B-2), especially fluocinolone acetonide+PT-A
(0.25%) ointment processing group, and compared with fluocinolone acetonide group, display significant difference (##p<0.01) (Fig. 8 C).And fluocinolone acetonide+PT-
A (5%) is compared with fluocinolone acetonide group though ointment processing group is improved the trend of improvement degree and is not reached significant difference (not
significant,ns)。
8. embodiment 9
Analyses of the PT-A to influence mouse ear skin thickness
ICR mouse (7-9 week old) are divided into control group (mediator (Vehicle)) and three groups of experimental groups first, wherein three
Group experimental group is respectively PT-A (content 25mg/g) ointment processing group, can founding easypro emulsifiable paste, (CLOBETASOL Cream mix emulsifiable paste
Base chloramphenicol propionate content is 0.25mg/g) (TOPSYM Cream mix emulsifiable paste for processing group and the net hydrophilic ointment of appropriate skin
Base fluocinolone acetonide content is 0.25mg/g) processing group.
Control group ear smears emulsifiable paste base (being free of an active ingredient) 10mg daily；And experimental group then ear per natural gift
Not Tu Mo a 10mg test emulsifiable paste, continuously smear fortnight.
Before coating and ear thickness is measured within every 2 to 4 days after coating, and the ear thickness before coating is set to 100%, is seen
Examine ear thickness variation situation.After animal is sacrificed, its inflamed sites skin is removed and is soaked in 4% formaldehyde and is fixed, is connect
It sample with rip cutting into after 6 μ m thicks, then is dyed with Hematoxylin-eosin, to assess skin disease degree, including upper skin depth
Degree, parakeratosis or hyperplasia etc..As a result as illustrated in figs. 9a and 9b.
It is understood according to Fig. 9 A and Fig. 9 B, the ear thickness variation of PT-A experimental groups is consistent with control group, does not cause apparent
Variation, however experimental group found easypro emulsifiable paste and appropriate skin two groups of net hydrophilic ointment coating 7 to 14 days after, ear thickness difference
For the 71-79% and 80-81% of thickness before coating, have apparent thinning trend (compared with control group, * p<0.05, * * p<
0.01)。
9. embodiment 10
Impact analysis of the PT-A for the skin thickness caused by reducing steroids
In the present embodiment, the PT-A ointment that continuous smearing is mixed with steroids assesses its influence for ear skin thickness.
Implementation step is as follows：
ICR mouse (7-9 week old) are divided into control group (mediator), control group (Clobetasol) and two groups of experiments first
Group, wherein two groups of experimental groups are respectively PT-A (content 25mg/g) ointment processing group mixed with PT-A (content 25mg/g) can stand it is easypro
Emulsifiable paste (CLOBETASOL Cream content 0.25mg/g) (the Clobetasol+PT-A) (weight ratios of PT-A than CLOBETASOL
For 100:1) ointment processing group.
Control group ear smears emulsifiable paste base (being free of an active ingredient) 10mg daily；Control group ear smears one daily
Secondary 10mg's founds easypro emulsifiable paste (CLOBETASOL Cream mix chloramphenicol propionate content 0.25mg/g after emulsifiable paste base)；
Then ear smears the test ointment of a 10mg to two groups of experimental group respectively daily, continuous to smear 14 days.
Before coating and ear thickness is measured within every 2 to 4 days after coating, and the ear thickness before coating is set to 100%, is seen
Examine ear thickness variation situation.After animal is sacrificed, its inflamed sites skin is removed and is soaked in 4% formaldehyde and is fixed, is connect
It sample with rip cutting into after 6 μ m thicks, then is dyed with Hematoxylin-eosin, to assess skin disease degree, including upper skin depth
Degree, parakeratosis or hyperplasia etc..As a result as shown in Figure 10 A and Figure 10 B.
It is understood according to Figure 10 A and Figure 10 B, the PT-A groups ear thickness variation of experimental group is consistent with control group, does not cause
Significant change；It is substantially thinning that the PT-A mixing of experimental group can found easypro emulsifiable paste group ear thickness, and coating is after 7 to 14 days to be thick before coating
The 77-83% of degree, close with control group 71-79% (compared with control group, * p<0.05, * * p<0.01), however PT-A mixing can
The 86% of 3 days thickness about before coating after vertical easypro emulsifiable paste group coating, hence it is evident that compared with 73% thickness (compared with the control group, #p of control group<
0.05)。
Embodiment 11
Compared with PT-A causes the effect of skin adverse reaction to be assessed with commercial product
First by C57BL/6 mouse (6-8 week old) back hair cutting, and by mouse be divided into control group, control group and
Experimental group.
Do not give mouse any processing in control group；Then 10mg Rinderon ointment is applied in control group small
Mouse back, is administered once per day for the treatment of, and continuously gives 60 days；And 10mg PT-A ointment is then applied to mouse back in experimental group,
It is administered once per day for the treatment of, continuously gives 60 days.
The degree of back part of animal skin adverse reaction is assessed afterwards, including the projects such as drying, rubescent, furfur, and is taken a picture.It will
After animal is sacrificed, its back is taken not smear the skin (control group) at ointment position or smears (control group and the experiment at ointment position
Group) skin carries out the Hematoxylin-eosin dyeing of tissue, as a result as shown in Figure 11 A and Figure 11 B.
Figure 11 A show, control group compared with control group after imiquimod is given, can significantly cause mouse skin drying with
Furfur phenomenon, however after PT-A being given in experimental group 60 days, mouse skin maintains normal appearance, identical with control group.
Figure 11 B show that control group can significantly cause the thinning phenomenon of mouse skin compared with control group, however in experimental group
After giving PT-A 60 days, mouse skin epidermis maintains normal thickness, identical with control group.
Embodiment 12
Human skin repetitive stimulation and sensitivity test result.
In the present embodiment, 50 subjects are tested altogether, and PT-A (content 25mg/g) ointment is applied to the patch of subsensitivety first
On cloth, then it is covered in region under the behind shoulder blade of subject.After when 24 is small, patch is removed.Every retest in 2 days,
3 tests are carried out in Yu Yizhou, carry out irritation test within continuous 3 weeks.Preceding and progress sensitivity test is tested in the 2-9 times
Before, rubefaction and oedema situation are observed, totally 9 results.
After 10-14 days, 50 subjects are applied to area under its behind shoulder blade with PT-A (content 25mg/g) ointment again
Domain.After when 24 and 48 are small, its rubefaction and oedema situation are assessed respectively, this is sensitivity test.As a result such as Figure 11 institutes
Show..
Figure 11 is the results show that PT-A will not cause human skin irritation and allergic reaction.
Embodiment 13
PT-A is in White Rabbit skin repetitive stimulation result of the test
First by 3 2.0-3.0kg new zealand white rabbits back hair cuttings, then by PT-A (content 25mg/g) ointment apply
In on the gauze of 1 inch × 1 inch size, and with artificial dressing fixation be attached at back right side area 24 it is small when after, remove
Gauze and artificial dressing, and tested skin is cleaned with distilled water, it smears within continuous 17 days.Control substance of plant drug (steams for first 10 days for injection
Distilled water, latter 7 days are no sample ointment), then it is equally applied on the gauze of same size, and left side is attached at artificial dressing fixation
Region.24 it is small when after, remove gauze and artificial dressing, and tested skin is cleaned with distilled water, smear within continuous 17 days.
After removing artificial dressing and gauze daily, start to observe whether animal skin generates erythema and edema situation, observe
Time Continuous 17 days.It is scored according to dermoreaction determinating reference table, then the fraction to be scored with this calculates the stimulation of skin single
Property coefficient PII (primary irritation index), the coefficient assessment skin drawn institute after test substances repeat to give
The stimulate the reaction of generation, the results are shown in Table 1.
Table 1, the White Rabbit skin repetitive stimulation result of the test of PT-A (content 25mg/g) ointment processing
Primary stimulus fraction (primary irritation score, PIS)
Primary stimulus fraction=experiment number of components-control number of components
Number 1001：19-3=16
Number 1002：0-0=0
Number 1003：8-1=7
Skin single irritation FACTOR P II
Skin single irritation FACTOR P II=primary stimuluses fraction/test number of days
Number 1001：(16/17=0.9 slight stimulation)
Number 1002：0/17=0 (non-stimulated)
Number 1003：7-17=0.4 (non-stimulated)
Table 1 is the results show that PT-A ointment is shown as slight stimulation reaction in 1 animal, remaining 2 then to be non-stimulated
Property.
Although the present invention is disclosed above with preferred embodiment, however, it is not to limit the invention, any to be familiar with this skill
Skill person, without departing from the spirit and scope of the present invention, when can make a little change and retouch, therefore protection scope of the present invention
When subject to appended claims institute defender.
Claims (42)
1. a kind of Chinese herbal medicine extract is used to prepare the purposes of the drug for the treatment of skin disease, wherein the Chinese herbal medicine extract
Preparing raw material includes Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony.
2. Chinese herbal medicine extract as described in claim 1 is used to prepare the purposes of the drug for the treatment of skin disease, wherein in this
It prepares in raw material, the Radix Glycyrrhizae, the radix bupleuri, the radix scutellariae, the weight ratio of the Schisandra chinensis and the Chinese herbaceous peony are about 1-5：1-
5：1-5：1-5：1-5.
3. Chinese herbal medicine extract as described in claim 1 is used to prepare the purposes of the drug for the treatment of skin disease, wherein described
Chinese herbal medicine extract system is obtained by the extracting process comprised the following steps：
(a) this is prepared to the Radix Glycyrrhizae in raw material, radix bupleuri, radix scutellariae, Schisandra chinensis to mix to form raw mixture with Chinese herbaceous peony；And
(b) raw mixture is subjected to extraction processing procedure with solvent.
4. Chinese herbal medicine extract as claimed in claim 3 is used to prepare the purposes of the drug for the treatment of skin disease, wherein this is molten
Agent includes water or organic solvent.
5. Chinese herbal medicine extract as claimed in claim 4 is used to prepare the purposes of the drug for the treatment of skin disease, wherein described
Organic solvent includes alcohols, ketone, acids or esters.
6. Chinese herbal medicine extract as claimed in claim 5 is used to prepare the purposes of the drug for the treatment of skin disease, wherein described
Alcohols includes methanol or ethyl alcohol.
7. Chinese herbal medicine extract as claimed in claim 3 is used to prepare the purposes of the drug for the treatment of skin disease, wherein described
Solvent is ethyl alcohol.
8. Chinese herbal medicine extract as described in claim 1 is used to prepare the purposes of the drug for the treatment of skin disease, wherein described
Radix Glycyrrhizae includes licorice or honey-fried licorice root, and the radix bupleuri includes raw Bupleurum Chinese or Gao Shi radix bupleuri, and the radix scutellariae includes withered and yellow a kind of reed mentioned in ancient books or item
Radix scutellariae, the Schisandra chinensis includes fructus schisandrae or kadsura longepedunculata, and the Chinese herbaceous peony includes the radix paeoniae rubrathe, Radix Paeoniae Alba or tree peony.
9. Chinese herbal medicine extract as described in claim 1 is used to prepare the purposes of the drug for the treatment of skin disease, wherein described
Radix Glycyrrhizae is licorice, the radix bupleuri is Bupleurum Chinese, the radix scutellariae is withered and yellow a kind of reed mentioned in ancient books, the Schisandra chinensis is five northern tastes and the Chinese herbaceous peony
For the radix paeoniae rubrathe.
10. Chinese herbal medicine extract as claimed in claim 9 is used to prepare the purposes of the drug for the treatment of skin disease, wherein in this
It prepares in raw material, the licorice, the Bupleurum Chinese, described withered and yellow a kind of reed mentioned in ancient books, the weight ratio of the fructus schisandrae and the radix paeoniae rubrathe are
About 1：1：1：1：1.
11. Chinese herbal medicine extract as claimed in claim 10 is used to prepare the purposes of the drug for the treatment of skin disease, wherein should
Chinese herbal medicine extract system is obtained by the extracting process comprised the following steps：
This is prepared to the licorice in raw material, the Bupleurum Chinese, described withered and yellow a kind of reed mentioned in ancient books, the fructus schisandrae to mix with the radix paeoniae rubrathe
It closes to form raw mixture；And
The raw mixture is subjected to extraction processing procedure with solvent.
12. Chinese herbal medicine extract as claimed in claim 11 is used to prepare the purposes of the drug for the treatment of skin disease, wherein should
Solvent is ethyl alcohol.
13. Chinese herbal medicine extract as described in claim 1 is used to prepare the purposes of the drug for the treatment of skin disease, the wherein skin
Skin disease includes autoimmunity related skin complaints or infectious skin disease.
14. Chinese herbal medicine extract as claimed in claim 13 is used to prepare the purposes of the drug for the treatment of skin disease, wherein institute
Stating autoimmunity related skin complaints includes silver bits disease, allergic dermatitis or Atopic dermatitis.
15. Chinese herbal medicine extract as described in claim 1 is used to prepare the purposes of the drug for the treatment of skin disease, wherein this is controlled
The drug of skin disease is treated as Topical dosage forms, and the Topical dosage forms include ointment, emulsion, liquor or gel.
16. Chinese herbal medicine extract as described in claim 1 be used to prepare treatment skin disease drug purposes, further include by
The Chinese herbal medicine extract is used to prepare the purposes of the drug for the treatment of skin disease together with steroids.
17. Chinese herbal medicine extract as claimed in claim 16 is used to prepare the purposes of the drug for the treatment of skin disease, wherein should
Chinese herbal medicine extract and the weight ratio of the steroids are about 5:1-200:1.
18. Chinese herbal medicine extract as claimed in claim 16 is used to prepare the purposes of the drug for the treatment of skin disease, wherein institute
Stating steroids can including dexamethasone, fluorometholone, medrysone, betamethasone, triamcinolone, prednisone, prednisolone or hydrogenation
Pine.
19. Chinese herbal medicine extract as claimed in claim 16 is used to prepare the purposes of the drug for the treatment of skin disease, wherein should
The drug of skin disease is treated as Topical dosage forms, and the Topical dosage forms include ointment, emulsion, liquor or gel.
20. a kind of Chinese herbal medicine extract, which is used to prepare, to be improved with the purposes of the drug of the side effect of steroid therapy skin disease,
The raw material for preparing of the wherein Chinese herbal medicine extract includes Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony.
21. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein prepared in this in raw material, the Radix Glycyrrhizae, the radix bupleuri, the radix scutellariae, the Schisandra chinensis and the Chinese herbaceous peony
The weight ratio of medicine is about 1-5：1-5：1-5：1-5：1-5.
22. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, the wherein Chinese herbal medicine extract obtained by the extracting process that comprises the following steps：
(a) this is prepared to the Radix Glycyrrhizae in raw material, radix bupleuri, radix scutellariae, Schisandra chinensis to mix to form raw mixture with Chinese herbaceous peony；And
(b) raw mixture is subjected to extraction processing procedure with solvent.
23. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the solvent include water or organic solvent.
24. Chinese herbal medicine extract as claimed in claim 23 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the organic solvent include alcohols, ketone, acids or esters.
25. Chinese herbal medicine extract as claimed in claim 24 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the alcohols include methanol or ethyl alcohol.
26. Chinese herbal medicine extract as claimed in claim 23 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the solvent be ethyl alcohol.
27. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the Radix Glycyrrhizae include licorice or honey-fried licorice root, the radix bupleuri include raw Bupleurum Chinese or Gao Shi radix bupleuri, institute
State radix scutellariae include withered and yellow a kind of reed mentioned in ancient books or radix scutellariae, the Schisandra chinensis include fructus schisandrae or kadsura longepedunculata, and the Chinese herbaceous peony include the radix paeoniae rubrathe,
Radix Paeoniae Alba or tree peony.
28. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the Radix Glycyrrhizae is licorice, the radix bupleuri is Bupleurum Chinese, the radix scutellariae is withered and yellow a kind of reed mentioned in ancient books, the five tastes
Son is the radix paeoniae rubrathe for five northern tastes and the Chinese herbaceous peony.
29. Chinese herbal medicine extract as claimed in claim 28 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein being prepared in this in raw material, the licorice, the Bupleurum Chinese, described withered and yellow a kind of reed mentioned in ancient books, the fructus schisandrae
Weight ratio with the radix paeoniae rubrathe is about 1：1：1：1：1.
30. Chinese herbal medicine extract as claimed in claim 29 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, the wherein Chinese herbal medicine extract obtained by the extracting process that comprises the following steps：
This is prepared the licorice in raw material, the Bupleurum Chinese, described withered and yellow a kind of reed mentioned in ancient books, the fructus schisandrae mixed with the radix paeoniae rubrathe with
Form raw mixture；And
The raw mixture is subjected to extraction processing procedure with solvent.
31. Chinese herbal medicine extract as claimed in claim 30 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the solvent be ethyl alcohol.
32. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the skin disease include infectious skin disease or autoimmunity related skin complaints.
33. Chinese herbal medicine extract as claimed in claim 32 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the autoimmunity related skin complaints include silver bits disease, allergic dermatitis or atopic skin
It is scorching.
34. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the side effect include thinning of skin and/or blood vessel dilatation.
35. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the steroids include dexamethasone, fluorometholone, medrysone, betamethasone, triamcinolone, sprinkle Buddhist nun
Pine, prednisolone or hydrocortisone.
36. Chinese herbal medicine extract as claimed in claim 20 is used to prepare improvement with the side effect of steroid therapy skin disease
Drug purposes, wherein the drug of the treatment skin disease be Topical dosage forms, and the Topical dosage forms include ointment,
Emulsion, liquor or gel.
37. a kind of medical composition for slowing down skin disease, including：
The raw material for preparing of Chinese herbal medicine extract, wherein the Chinese herbal medicine extract includes
Radix Glycyrrhizae, radix bupleuri, radix scutellariae, Schisandra chinensis and Chinese herbaceous peony；And
Steroids,
Wherein the Chinese herbal medicine extract has effects that reduce side effect caused by the steroids and/or compared to exclusive use
The steroids has effects that reduce the effective dose needed for the steroids.
38. slow down the medical composition of skin disease as claimed in claim 37, wherein prepared in this in raw material, it is described sweet
Careless, described radix bupleuri, the radix scutellariae, the weight ratio of the Schisandra chinensis and the Chinese herbaceous peony are about 1-5：1-5：1-5：1-5：1-5.
39. the as claimed in claim 37 medical composition for slowing down skin disease, wherein the Chinese herbal medicine extract with it is described
The weight ratio of steroids is about 5:1-200:1.
40. the as claimed in claim 37 medical composition for slowing down skin disease, wherein the steroids include dexamethasone,
Fluorometholone, medrysone, betamethasone, triamcinolone, prednisone, prednisolone or hydrocortisone.
41. the medical composition as claimed in claim 37 for slowing down skin disease, the wherein medical composition are local administration
Dosage form or Parenteral.
42. the medical composition as claimed in claim 37 for slowing down skin disease, the wherein medical composition are local administration
Dosage form, the wherein Topical dosage forms include ointment, emulsion, liquor or gel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105139426 | 2016-11-30 | ||
| TW105139426A TWI610679B (en) | 2016-11-30 | 2016-11-30 | Use of an ethanol extract of chinese herb and a pharmaceutical composition containing the ethanol extract of chinese herb and a steroid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108114061A true CN108114061A (en) | 2018-06-05 |
| CN108114061B CN108114061B (en) | 2022-01-25 |
Family
ID=61728551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611205417.7A Active CN108114061B (en) | 2016-11-30 | 2016-12-21 | Use of Chinese herbal medicine extract and pharmaceutical composition containing the same and steroid |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6738787B2 (en) |
| CN (1) | CN108114061B (en) |
| TW (1) | TWI610679B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110694026A (en) * | 2019-10-15 | 2020-01-17 | 甘肃医学院附属医院 | Traditional Chinese medicine composition for treating hormone-dependent dermatitis |
| CN115381885A (en) * | 2022-08-10 | 2022-11-25 | 上海中医药大学附属曙光医院 | A Chinese medicinal composition for treating or relieving asthenopia or video syndrome |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102107748B1 (en) * | 2019-08-30 | 2020-05-08 | 주식회사 아제라바이오텍 | A Compositions for anti-itching of skin and preventing or improvement of atopic dermatitis comprising extract from Ageratum houstonianum, Schisandra chinensis and Bupleurum falcatum |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590105A (en) * | 2008-05-30 | 2009-12-02 | 财团法人工业技术研究院 | Chinese herbal medicine extract of inducing immune cells to generate interferon and activation Toll sample receptor and preparation method thereof |
| CN102671042A (en) * | 2012-04-25 | 2012-09-19 | 王伟 | Traditional Chinese medicinal composition for treating acne and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0477431A (en) * | 1990-07-19 | 1992-03-11 | Kanebo Ltd | Interferon-inducing agent |
| DE60117711T2 (en) * | 2001-04-02 | 2006-11-09 | Li, Hongfen | ANTINEOPLASTIC MEDICAMENT |
| KR101483440B1 (en) * | 2008-05-02 | 2015-01-19 | (주)아모레퍼시픽 | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same |
-
2016
- 2016-11-30 TW TW105139426A patent/TWI610679B/en active
- 2016-12-21 CN CN201611205417.7A patent/CN108114061B/en active Active
-
2017
- 2017-11-16 JP JP2017220953A patent/JP6738787B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590105A (en) * | 2008-05-30 | 2009-12-02 | 财团法人工业技术研究院 | Chinese herbal medicine extract of inducing immune cells to generate interferon and activation Toll sample receptor and preparation method thereof |
| CN102671042A (en) * | 2012-04-25 | 2012-09-19 | 王伟 | Traditional Chinese medicinal composition for treating acne and preparation method thereof |
Non-Patent Citations (14)
| Title |
|---|
| （美）弗兰克尔: "《临床皮肤病学指南》", 31 May 2001, 天津科技翻译出版公司 * |
| YOKO YOSHIHISA等: "The Traditional Japanese Formula Keishibukuryogan", 《MEDIATORS OF INFLAMMATION》 * |
| 兰承祥: "《国家中青年名中医·兰承祥》", 30 June 2016, 中原农民出版社 * |
| 张堂德等: "外用糖皮质激素的副作用及防治", 《皮肤性病诊疗学杂志》 * |
| 新浪博客: "过敏煎与脱敏汤", 《HTTPS://WWW.WEIBO.COM/P/23041889A868810102X1W9?MOD=ZWENZHANG》 * |
| 朱文元等: "皮质类固醇外用的副作用", 《国际皮肤性病学杂志》 * |
| 林小田等: "《皮肤病中医辨治及食疗》", 30 June 2002, 羊城晚报出版社 * |
| 林琳等: "抑炎细胞因子IL-37的研究新进展", 《中国免疫学杂志》 * |
| 王晓菲等: "Toll 样受体与特应性皮炎的研究进展", 《基础医学与临床》 * |
| 王燕: "《药物商品学》", 31 March 1997, 中国科学技术出版社 * |
| 王秀华: "外用激素治疗皮肤病优越性及注意事项", 《中国医疗美容》 * |
| 秦文瀚等: "《国家基本药物临床应用手册》", 30 September 2000, 北京医科大学出版社 * |
| 贾公孚等: "《简明中西药新用联用手册》", 31 August 1998, 湖南科学技术出版社 * |
| 赖亭吉等: "Toll样受体在皮肤病发病及治疗中的作用", 《临床皮肤科杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110694026A (en) * | 2019-10-15 | 2020-01-17 | 甘肃医学院附属医院 | Traditional Chinese medicine composition for treating hormone-dependent dermatitis |
| CN115381885A (en) * | 2022-08-10 | 2022-11-25 | 上海中医药大学附属曙光医院 | A Chinese medicinal composition for treating or relieving asthenopia or video syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201821095A (en) | 2018-06-16 |
| CN108114061B (en) | 2022-01-25 |
| JP6738787B2 (en) | 2020-08-12 |
| TWI610679B (en) | 2018-01-11 |
| JP2018090568A (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pawar et al. | Phytosome as a novel biomedicine: a microencapsulated drug delivery system | |
| JPH07277944A (en) | Melanism inhibitor | |
| US20220218595A1 (en) | Method of using soothing cream including maca root extract as an active ingredient | |
| CN102440928B (en) | Traditional Chinese medicine composition and preparation with skin microcirculation promotion function and preparation method thereof | |
| CN108114061A (en) | Use of Chinese herbal medicine extract and pharmaceutical composition containing the same and steroid | |
| US9554985B2 (en) | Agent for promoting hair growth and method for preparing same | |
| KR101434717B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extracts of Panax ginseng and Hijikia fusiforme | |
| CN112190593A (en) | Polysaccharide composition for inhibiting TRPV1 pathway and preparation method and application thereof | |
| Lee et al. | A combination of Olea europaea leaf extract and Spirodela polyrhiza extract alleviates atopic dermatitis by modulating immune balance and skin barrier function in a 1-chloro-2, 4-dinitrobenzene-induced murine model | |
| CN105581974B (en) | A kind of topical composition | |
| CN109620782B (en) | Plant composition with whitening and spot-fading effects | |
| EP2596787A1 (en) | New use of hesperetin | |
| CN105288418B (en) | A kind of micro emulsion gel paste and preparation method thereof for treating baby diarrhea | |
| KR20150097336A (en) | Cosmetic Composition have Atopic cure and prevention efficacy | |
| WO2009043671A1 (en) | Use of a silybum marianum extract | |
| KR101819418B1 (en) | Compositions for promoting hair growth and preventing hair loss containing complex of ginsenoside Rb1, Rc, Rh1 and Rg3 as active ingredients | |
| KR20130036984A (en) | Cosmetic composition for inhibiting hair loss and enhanching hair growth | |
| EP4230214A1 (en) | Composition for preventing and treating anti-inflammatory and autoimmune diseases and non-alcoholic fatty liver disease, comprising extract derived from centipeda minima | |
| KR101574555B1 (en) | Composition for enhancing hair growth containing ginsenoside Rg3, Rg5 and Rk1 as active ingredients | |
| CN111298075B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| KR20180115610A (en) | Compositions for promoting hair growth and preventing hair loss containing complex of ginsenoside Rb1, Rc, Rh1 and Rg3 as active ingredients | |
| CN105687350B (en) | Traditional Chinese medicine composition for improving ischemic cerebral apoplexy and application thereof | |
| Tang et al. | Poplar bark lipids enhance mouse immunity by inducing T cell proliferation and differentiation | |
| CA2607544A1 (en) | A pharmaceutical formulation and its use for the treatment of acquired immune deficiency syndrome (aids) and other aids related diseases and a process for its preparation | |
| JP3822517B2 (en) | Topical skin preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |